What are the recommended treatment options for insomnia in children and adolescents compared with adults?

Treatment of Insomnia in Young Patients and Adults

For adults with chronic insomnia, cognitive behavioral therapy for insomnia (CBT-I) should be the initial treatment, with pharmacotherapy reserved only for those who fail CBT-I; in children and adolescents, behavioral interventions and sleep hygiene education are first-line, with medications playing an extremely limited role and no FDA-approved options available for pediatric insomnia. 1

Adults with Chronic Insomnia

First-Line Treatment: CBT-I

The American College of Physicians provides a strong recommendation that all adult patients receive CBT-I as initial treatment for chronic insomnia disorder 1. This is based on moderate-quality evidence showing:

• Improved global outcomes (increased remission, treatment response, reduced Insomnia Severity Index scores)
• Improved sleep parameters (reduced sleep onset latency, reduced wake after sleep onset, improved sleep efficiency)
• Benefits persist in older adults specifically 1

CBT-I can be delivered through multiple modalities: in-person (individual or group), telephone-based, web-based modules, or self-help books. All delivery methods show effectiveness 1.

Second-Line: Pharmacotherapy

Only after CBT-I has failed should you consider adding medications, using shared decision-making that explicitly discusses benefits, harms, and costs 1. This is a weak recommendation based on low-quality evidence.

Medications with evidence in adults:

• Eszopiclone and zolpidem: Low-to-moderate quality evidence for improved sleep onset latency, total sleep time, and wake after sleep onset 1
• Suvorexant (orexin antagonist): Moderate-quality evidence for improved treatment response and sleep outcomes 1
• Doxepin: Moderate-quality evidence in older adults for improved ISI scores and sleep outcomes 1
• Ramelteon: Low-quality evidence, no statistically significant difference from placebo in general population 1

Critical caveat: FDA approval is only for short-term use (4-5 weeks). Observational studies link hypnotics to serious adverse effects including dementia, serious injury, and fractures 1. FDA labels warn of daytime impairment, sleep-driving, behavioral abnormalities, and worsening depression. Evidence is insufficient for long-term use safety.

Children and Adolescents with Insomnia

Fundamental Differences from Adults

Insomnia in pediatric populations is multifactorial and age-dependent 2. In typically developing children, the primary cause is behavioral, but this becomes more complex with comorbidities. The clinical presentation changes with developmental stage, requiring age-appropriate interventions 3, 4.

First-Line Treatment: Behavioral Interventions

Behavioral therapy is the cornerstone of pediatric insomnia treatment 5, 4:

For infants and toddlers:

• Address negative sleep associations formed in the first year of life 6
• Parental psychoeducation on sleep development 2, 4
• Establish consistent bedtime routines 4

For school-aged children:

• CBT-I techniques adapted for children: bedtime shifts (including sleep restriction), stimulus control, thought challenging, psychoeducation, relaxation techniques 5
• Parent integration is highly recommended 5
• Address sleep hygiene and external synchronizers 4

For adolescents:

• CBT-I with focus on psychophysiological factors 6
• Address circadian rhythm disorders, particularly delayed sleep phase syndrome 4
• Target sleep hygiene violations common in this age group 6

Pharmacotherapy in Pediatrics: Extremely Limited Role

No medications are FDA-approved for pediatric insomnia 7. Medications should only be considered after well-conducted non-pharmacological measures have failed, with particular attention to benefit-risk ratio 4.

Melatonin has the most limited role, primarily reserved for:

• Neurodevelopmental disorders 4
• Neurogenetic disorders 4
• After failure of behavioral interventions 4

The safety profile is fundamental in pediatric insomnia pharmacotherapy, and use should be individualized with regular re-evaluation 4, 6.

Special Population: Autism Spectrum Disorder

Children with ASD have insomnia prevalence of 53-78% compared to 26-32% in typically developing children 2. The practice pathway emphasizes:

• Systematic identification using validated tools (Children's Sleep Habits Questionnaire)
• Recognition that insomnia is multifactorial (behavioral, medical, neurologic, psychiatric comorbidities, medication adverse effects)
• Treatment may improve problematic daytime behaviors 2

Key Clinical Pitfalls

In adults: Jumping to pharmacotherapy without attempting CBT-I first. The evidence strongly supports behavioral intervention as initial treatment, yet medications are frequently prescribed first in clinical practice.

In children: Overlooking underlying sleep disorders when parents present with behavioral concerns (aggression, impulsivity, inattention). The sleep disorder may be the primary driver 2. Also, prescribing medications when behavioral interventions haven't been adequately attempted—remember, no pediatric medications are FDA-approved for this indication 7.

Across all ages: Failing to assess 24-hour sleep-wake patterns, chronotype, and comorbidities before initiating treatment 4.